Trial Profile
An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms POEM
- Sponsors Pfizer; ViiV Healthcare
- 13 Mar 2019 Status changed from active, no longer recruiting to completed.
- 28 Jun 2017 Planned End Date changed from 31 Oct 2018 to 26 Feb 2019.
- 28 Jun 2017 Planned primary completion date changed from 31 Oct 2018 to 26 Feb 2019.